Table 1 Baseline characteristics of enrolled patients with septic shock
All patients (N = 78) | AVP group (n = 40) | NE group (n = 38) | P value | |
|---|---|---|---|---|
Age, years | 66 (56 – 71) | 67 (56 – 73) | 64 (55 – 69) | 0.206 |
Gender, male | 49 (62.8) | 25 (62.5) | 24 (63.2) | 0.952 |
Causes of septic shocka | 0.522 | |||
Pneumonia | 39 (50.0) | 23 (57.5) | 16 (42.1) | |
Intraabdominal infection | 22 (28.2) | 10 (25.0) | 12 (31.6) | |
Urogenital infection | 16 (20.5) | 7 (17.5) | 9 (23.7) | |
Cather related infection | 5 (6.4) | 4 (10.0) | 1 (2.6) | |
Endocarditis | 2 (2.6) | 1 (2.5) | 1 (2.6) | |
Othersb | 3 (3.8) | 1 (2.5) | 2 (5.3) | |
MAP before initial resuscitation, mmHg | 52 (45-57) | 52 (46-57) | 54 (44-60) | 0.255 |
CVP before initial resuscitation, mmHg | 7 (4-9 | 6 (4-8) | 7 (5-9) | 0.303 |
MAP at the time of vasopressor initiated, mmHg | 55 (51-60) | 54 (50-60) | 56 (52-60) | 0.309 |
CVP at the time of vasopressor initiated, mmHg | 11 (9-14) | 10 (8-14) | 11 (9-13) | 0.954 |
Total bilirubin, mg/dL | 1.05 (0.50-2.30) | 1.15 (0.50-2.38) | 0.95 (0.50-2.01) | 0.802 |
Serum creatinine, mg/dL | 1.34 (0.93-1.99) | 1.48 (0.84-1.94) | 1.30 (0.98-2.26) | 0.960 |
Lactic acid, mmol/L | 3.61 (2.40-5.44) | 3.53 (2.41-5.48) | 4.11 (2.39-5.65) | 0.699 |
Procalcitonin, ng/mL | 12.70 (3.29-37.70) | 14.35 (3.52-45.66) | 9.91 (2.62-31.42) | 0.484 |
C-reactive protein, mg/mL | 13.96 (6.87-24.35) | 16.04 (8.29-26.10) | 12.99 (6.09-23.17) | 0.492 |
Maximum NE dose during study period, ug/kg/min | 0.68 (0.40-1.20) | 0.68 (0.40-1.45) | 0.68 (0.40-1.03) | 0.195 |
SAPS3 | 74 (63 – 84) | 75 (66 – 92) | 72 (61 – 82) | 0.192 |
SOFA score | 10 (8 – 12) | 10 (8 – 12) | 10 (7 – 11) | 0.793 |
Clinical status on randomization | ||||
MAP, mmHg | 77 (71 – 81) | 75 (68 – 81) | 77 (74 – 80) | 0.237 |
CVP, mmHg | 10 (8 – 14) | 10 (8 – 14) | 10 (8 – 14) | 0.811 |
Need for mechanical ventilation | 54 (69.2) | 33 (82.5) | 21 (55.3) | 0.009 |
Need for renal replacement therapy | 22 (28.2) | 11 (27.5) | 11 (28.9) | 0.887 |
Need for dobutamine | 6 (7.7) | 1 (2.5) | 5 (13.2) | 0.104 |
SOFA score | 12 (10 – 15) | 12 (11 – 15) | 12 (9 – 15) | 0.413 |
PF ratio | 164.5 (100.2 – 264.1) | 132.4 (96.1 – 202.6) | 198.9 (133.0 – 290.7) | 0.014 |
Total bilirubin, mg/dL | 1.30 (0.68 – 3.70) | 1.30 (0.63 – 2.93) | 1.35 (0.65 – 4.23) | 0.845 |
Serum creatinine, mg/dL | 1.12 (0.72 – 1.95) | 1.10 (0.75 – 1.92) | 1.23 (0.68 – 1.95) | 0.881 |
Corticosteroid treatment | 72 (96.0) | 38 (97.4) | 34 (94.4) | 0.605 |
Time to randomization | 24.2 (13.1 – 44.1) | 27.4 (15.1 – 44.4) | 19.2 (11.5 – 33.1) | 0.108 |
Total vasopressor duration before tapering first vasoactive agent, hours | 24.2 (13.1 – 41.8) | 29.0(15.1 – 43.9) | 19.2 (11.5 – 33.1) | 0.127 |
Copeptin, pg/mL (n = 76) | 162 (107 – 220) | 148 (100 – 237) | 170 (113 – 215) | 0.640 |